This Just In: Upgrades and Downgrades

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." Today, we'll show you whether those bigwigs actually know what they're talking about. To help, we've enlisted Motley Fool CAPS to track the long-term performance of Wall Street's best and worst.

And speaking of the best ...
When it comes to the emerging field of robotic surgery, there are three key names investors tend to focus on: Intuitive Surgical (NASDAQ: ISRG  ) , MAKO Surgical (UNKNOWN: MAKO.DL  ) , and Hansen Medical (NASDAQ: HNSN  ) . As it so happens, all three of these companies made news last week. But there's no question which of the three came out of the week looking better than all the others: Hands down, it was Intuitive.

On Thursday, you see, a report filtered out of Bloomberg announcing that the U.S. Food and Drug Administration has begun asking questions about "complications" surgeons experience when using Intuitive's da Vinci surgical robots. Worries that this could turn into something serious sparked an immediate 11% sell-off in the stock Thursday -- a sell-off that quickly morphed into a buying frenzy Friday, when several analysts leapt to the company's defense:

  • William Blair: "We firmly believe that [da Vinci] is safe and effective, and that the recent concerns about increasing rates of complication are to be expected with any medical device."
  • Cantor Fitzgerald: This is all a "gross overreaction" to the FDA news.
  • Mizuho Securities: "Reports" of problems with da Vinci have "actually declined over time."
  • Janney Capital Markets: The stock is going back up, so buy it quick. "If management felt that there needed to be an explanation on the issues, they would've been much more aggressive in managing the Street's expectations."

Cantor itself took that advice to heart, changing its rating on Intuitive to "buy" in response to Thursday's sell-off. And as luck would have it, Cantor made its call just in time to catch the stock's rebound Friday. By the time markets had closed for the weekend, the stock had gained back 8.5%, and closed above $553.

You've heard about the best. But what of the rest?
Mirroring Intuitive's topsy-turvy week, MAKO Surgical and Hansen Medical took opposite directions last week -- despite reporting remarkably similar news events.

On Tuesday, MAKO reported losing $0.13 a share (two cents worse than forecast) on weaker-than-expected revenues. Regardless, a large increase in surgical procedures using the company's products got investors excited enough to bid up the shares by 16% over the ensuing two days. (Which seems a strange reaction to a reported loss.)

One day later, Hansen reported  a loss as well but encountered a much different reaction from investors. They sold off Hansen shares by 7% after the company delivered a $0.35-per-share loss when "only" a $0.14 loss had been expected. Revenues, at $4.3 million, were simultaneously negligible, and also about 27% worse than expected.

Of the two reports, Wall Street reacted only to the first, with Oppenheimer cutting its price target on MAKO Surgical, citing an "uncertain macro environment." (Funny, though, how things don't seem to be quite so uncertain over at Intuitive Surgical.) Of course, Oppenheimer still thinks MAKO shares should be worth $13, in spite of the uncertainty.

Foolish takeaway
Investor reactions notwithstanding, one thing seems crystal clear here: Of the three companies, only Intuitive Surgical is currently reporting profits, generating cash, and selling real products to real customers in quantities sufficient to make it a viable business. Meanwhile, analysts who follow MAKO and Hansen still don't see either company earning a profit this year, or next year, or even the year after that.

Make no mistake: Despite what I've pointed out, I'm still not a fan of Intuitive Surgical's stock. At 35 times earnings, and a price-to-free cash flow ratio only a little bit cheaper than that, the stock is grossly overpriced for the 18% long-term earnings growth it's expected to produce over the next five years.

Regardless, there's simply no question that in relative terms, Intuitive Surgical is "the best" robotic surgery company out there. As for MAKO and Hansen -- despite what their fans may say, neither one of these companies deserves the title of "the next Intuitive Surgical." They might eventually get bought out and turned into subsidiaries of Intuitive Surgical.

On the other hand, they could just as easily get competed out of existence by the real Intuitive Surgical.

Are stories of this demise greatly exaggerated?
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes there's a visible path to long-term growth persists. Will Intuitive capitalize or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key new hits -- so be sure to claim your copy by clicking here now.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 04, 2013, at 3:20 PM, Dawgpac wrote:

    The MAKO analyst updates post Q4:

    William Blair & Co: OUTPERFORM. "2013 Guidance is solid..valuation reasonable"

    Canaccord: HOLD. Reduced PT to $12 from $13. "Knee business turnaround not expected until Q2 2013 at best"

    Piper Jaffray: OVERWEIGHT. Price target: $23 Growth story again.

    Oppenheimer: MARKET PERFORM. Reduced PT to $13 from $14.

    Goldman Sachs: NEUTRAL. Price target: $16

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2289514, ~/Articles/ArticleHandler.aspx, 9/27/2016 3:08:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,213.27 118.44 0.65%
S&P 500 2,158.29 12.19 0.57%
NASD 5,299.79 42.30 0.80%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
HNSN $0.00 Down +0.00 +0.00%
Hansen Medical CAPS Rating: *
ISRG $717.00 Up +9.76 +1.38%
Intuitive Surgical CAPS Rating: ****
MAKO.DL $0.00 Down +0.00 +0.00%
MAKO Surgical CAPS Rating: ****